Amlodipine plus Losartan

DRUG6 trials

Sponsors

Hanmi Pharmaceutical Company Limited, Korea University Anam Hospital

Conditions

HealthyHypertension

Phase 1

A Bioequivalence Study of Amlodipine Plus Losartan Versus Amlodipine and Losartan

CompletedNCT01197001

Hanmi Pharmaceutical Company LimitedHealthy

Start: 2010-08-31End: 2010-11-30Target: 72Updated: 2011-04-27

A Bioequivalence Study of Amlodipine Plus Losartan Versus Amlodipine and Losartan

CompletedNCT01197014

Hanmi Pharmaceutical Company LimitedHealthy

Start: 2010-09-30End: 2010-12-31Target: 72Updated: 2011-04-27

The Pharmacokinetic Interaction Between Amlodipine and Losartan

CompletedNCT03912285

Korea University Anam HospitalHealthy

Start: 2008-01-10End: 2009-06-09Updated: 2019-04-12

Phase 2

Efficacy and Safety of Amlodipine and Losartan in Patients With Essential Hypertension

CompletedNCT00942344

Hanmi Pharmaceutical Company LimitedHypertension

Start: 2007-05-31End: 2007-12-31Updated: 2009-07-20

Phase 3

Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Essential Hypertension

CompletedNCT00940667

Hanmi Pharmaceutical Company LimitedHypertension

Start: 2008-05-31End: 2008-12-31Updated: 2016-10-12

Efficacy/Safety of Amlodipine Plus Losartan Versus Losartan in Patients With Essential Hypertension

CompletedNCT00940680

Hanmi Pharmaceutical Company LimitedHypertension

Start: 2008-04-30End: 2008-11-30Updated: 2009-07-16

Related Papers

Comparison of the efficacy and safety of fixed-dose amlodipine/losartan and losartan in hypertensive patients inadequately controlled with losartan: a randomized, double-blind, multicenter study.

2012-06-0115 citations

Evaluation of the dose-response relationship of amlodipine and losartan combination in patients with essential hypertension: an 8-week, randomized, double-blind, factorial, phase II, multicenter study.

2012-02-0111 citations

Comparative efficacy and safety profile of amlodipine 5 mg/losartan 50 mg fixed-dose combination and amlodipine 10 mg monotherapy in hypertensive patients who respond poorly to amlodipine 5 mg monotherapy: an 8-week, multicenter, randomized, double-blind phase III noninferiority study.

2011-12-0214 citations